Ms Contin (Morphine Sulfate)

Morphine sulfate works by binding to μ‑opioid receptors in the brain and spinal cord. This activation inhibits the release of neurotransmitters involved in pain signaling, reduces neuronal excitability, and alters the perception of pain. The result is analgesia, sedation, and a decrease in the emotional response to painful stimuli.

The dose of Ms Contin is individualized by the prescribing clinician based on the patient’s pain severity, prior opioid exposure, renal and hepatic function, and overall clinical condition. No fixed regimen is provided here; the prescriber will select the appropriate strength and dosing interval to achieve effective pain relief while minimizing adverse effects.

The safety of morphine sulfate during pregnancy and lactation is not well established. Because opioids can cross the placenta and appear in breast milk, Ms Contin should be used only if the potential benefit justifies the potential risk to the fetus or infant. Consultation with a specialist is recommended before use in these populations.

To order Ms Contin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any required temperature control) and the necessary import documentation.

Ms Contin is an extended‑release oral tablet, offering a smoother plasma‑level profile compared with immediate‑release morphine tablets that require multiple daily dosing. Compared with other long‑acting opioids such as oxycodone ER or fentanyl patches, Ms Contin provides a familiar morphine molecule with a predictable conversion factor, making it a common choice when a gradual, 12‑hour analgesic effect is desired.

Ms Contin tablets should be stored at ambient temperature, below 25 °C, in the original blister pack or container. Protect the product from moisture, direct sunlight and excessive heat to maintain potency and prevent degradation.

Ms Contin is taken orally, whole, with a full glass of water. The tablet must not be chewed, crushed, or split, as this could release the entire dose at once and increase the risk of serious adverse effects. Dosing intervals are typically every 12 hours, but the exact schedule is determined by the prescriber.

The most serious risks associated with Ms Contin include respiratory depression, profound sedation, hypotension, severe constipation leading to bowel obstruction, and the potential for dependence, abuse, or withdrawal. Patients should be monitored closely for signs of respiratory compromise, especially during dose titration, and educated about the importance of not exceeding the prescribed amount.

Ms Contin is contraindicated in patients with known hypersensitivity to morphine or any component of the formulation, in individuals with severe respiratory depression, acute or severe bronchial asthma, or paralytic ileus. Caution is also advised for patients with uncontrolled hypertension, head injury, or those receiving MAO inhibitors within 14 days.